[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-kAbusfQbhBnPzF7AVrPU8PlBtCCRfHmDTPNvLlsps0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"Gynuity Health Projects",[4],113,false,2,10,136604,3,39,[14,17,20,22,25,28,30,33],{"name":15,"count":16},"Postpartum Hemorrhage",21,{"name":18,"count":19},"Medical Abortion",12,{"name":21,"count":9},"Pregnancy",{"name":23,"count":24},"Preeclampsia",8,{"name":26,"count":27},"Abortion, Induced",5,{"name":29,"count":27},"Incomplete Abortion",{"name":31,"count":32},"Abortion in Second Trimester",4,{"name":34,"count":11},"Abortion, First Trimester",[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06492889","Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens","2025-06-30","Levonorgestrel",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06270056","Evaluation of Telemedicine Medical Abortion Service in Ecuador","2025-07","Misoprostol",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,91,264,541,563,597,628,646,671,697,715,733,756,780,807,825,843,864,882,906,931,999,1047,1084,1120,1154,1172,1195,1218,1239,1257],{"intervention":40,"totalTrials":8,"cells":55},{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":75,"PHASE4":87,"NA":89},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[63],{"nctId":64,"briefTitle":65,"status":66,"phases":67,"primaryCompletion":68,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":73},"NCT04676776","Assessing Use Of Mifepristone After Progestin Priming For Use As \"Missed Period Pills\"","UNKNOWN",[49],"2021-12","2021-01-25",139,[72],"Missed Menstrual Period",[40,74],"Mifepristone",{"trials":76,"activeCount":86,"soonestReadout":39},[77],{"nctId":37,"briefTitle":38,"status":78,"phases":79,"primaryCompletion":39,"completion":39,"start":80,"enrollment":81,"conditions":82,"interventions":85},"NOT_YET_RECRUITING",[49,50],"2024-07-22",286,[83,84],"Pregnancy Early","Pregnancy Related",[40,74],1,{"trials":88,"activeCount":58},[],{"trials":90,"activeCount":58},[],{"intervention":74,"totalTrials":92,"cells":93},17,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":114,"PHASE4":152,"NA":233},{"trials":95,"activeCount":58},[],{"trials":97,"activeCount":58},[],{"trials":99,"activeCount":58},[100,110],{"nctId":101,"briefTitle":102,"status":66,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT03972358","Assessing Medical Menstrual Regulation in the United States",[49],"2021-12-31","2020-02-12",284,[108],"Menstrual Regulation",[74,45],{"nctId":64,"briefTitle":65,"status":66,"phases":111,"primaryCompletion":68,"completion":68,"start":69,"enrollment":70,"conditions":112,"interventions":113},[49],[72],[40,74],{"trials":115,"activeCount":86,"soonestReadout":39},[116,120,130,140],{"nctId":37,"briefTitle":38,"status":78,"phases":117,"primaryCompletion":39,"completion":39,"start":80,"enrollment":81,"conditions":118,"interventions":119},[49,50],[83,84],[40,74],{"nctId":121,"briefTitle":122,"status":66,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT03269279","Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso",[50],"2019-12-31","2017-05-20",100,[128],"Medical; Abortion, Fetus",[74,45],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT02985229","Acceptability and Feasibility of Medical Abortion in Singapore","COMPLETED",[50],"2017-07","2016-10",130,[18],[74,45],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT02633761","Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death","TERMINATED",[50],"2018-12-30","2015-04-01",200,[149],"Fetal Death",[74,151],"Misoprostol 200mcg",{"trials":153,"activeCount":58},[154,164,175,185,195,205,215,223],{"nctId":155,"briefTitle":156,"status":133,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT01768299","Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks)",[51],"2014-05","2013-02",504,[162],"Complete Uterine Evacuation After Use of Study Drugs",[74,45],{"nctId":165,"briefTitle":166,"status":66,"phases":167,"primaryCompletion":168,"completion":168,"start":158,"enrollment":169,"conditions":170,"interventions":172},"NCT02708446","A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion",[51],"2016-12",320,[171],"Legally Induced Abortion Without Mention of Complication",[74,173,174],"Buccal misoprostol","Sublingual misoprostol",{"nctId":176,"briefTitle":177,"status":133,"phases":178,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},"NCT02720991","A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks",[51],"2015-04","2014-07",50,[183],"Abortion, 3 Months",[74,174],{"nctId":186,"briefTitle":187,"status":143,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT02342002","Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial",[51],"2018-12-31","2015-01",416,[193,21],"Missed Abortion",[74,45],{"nctId":196,"briefTitle":197,"status":133,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT02981030","Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine",[51],"2017-06-30","2016-11-23",102,[203],"Abortion, Therapeutic",[74,45],{"nctId":206,"briefTitle":207,"status":143,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT02704481","Non-surgical Alternatives to Treatment of Failed Medical Abortion",[51],"2019-01-16","2016-06-01",16,[213],"Abortion Failure",[74,45],{"nctId":216,"briefTitle":217,"status":133,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":181,"conditions":221,"interventions":222},"NCT01856985","Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation",[51],"2013-09","2013-04",[18],[45,74],{"nctId":224,"briefTitle":225,"status":143,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":211,"conditions":230,"interventions":232},"NCT04063904","Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia",[51],"2020-04-03","2021-04-03","2019-10-16",[231],"Second Trimester Abortion",[74,45],{"trials":234,"activeCount":58},[235,247,257],{"nctId":236,"briefTitle":237,"status":133,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT00680394","Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone",[52],"2008-05","2007-07",440,[243],"Pregnancy Termination",[245,246],"mifepristone","misoprostol",{"nctId":248,"briefTitle":249,"status":133,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT00994734","Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion",[52],"2011-02","2009-05",615,[255],"Termination of Pregnancy",[74],{"nctId":258,"briefTitle":259,"status":133,"phases":260,"primaryCompletion":180,"completion":180,"start":220,"enrollment":261,"conditions":262,"interventions":263},"NCT01811056","Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion",[52],401,[255],[74],{"intervention":45,"totalTrials":265,"cells":266},35,{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":280,"PHASE3":286,"PHASE4":332,"NA":384},{"trials":268,"activeCount":58},[],{"trials":270,"activeCount":58},[271],{"nctId":272,"briefTitle":273,"status":133,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT01539408","Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion in Nigeria",[48],"2010-10","2009-08",90,[29],[45],{"trials":281,"activeCount":58},[282],{"nctId":101,"briefTitle":102,"status":66,"phases":283,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":284,"interventions":285},[49],[108],[74,45],{"trials":287,"activeCount":58},[288,292,302,306,316,326],{"nctId":121,"briefTitle":122,"status":66,"phases":289,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":290,"interventions":291},[50],[128],[74,45],{"nctId":293,"briefTitle":294,"status":295,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":58,"conditions":299,"interventions":300},"NCT01710566","Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities","WITHDRAWN",[50],"2014-12","2013-07",[15],[45,301],"Oxytocin",{"nctId":131,"briefTitle":132,"status":133,"phases":303,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":304,"interventions":305},[50],[18],[74,45],{"nctId":307,"briefTitle":308,"status":133,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT00671060","Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy",[50],"2011-12","2008-10",153,[314],"Intrauterine Fetal Demise",[45,45],{"nctId":317,"briefTitle":318,"status":133,"phases":319,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT02163616","Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study",[50],"2016-05","2016-06","2015-09",635,[15],[45],{"nctId":327,"briefTitle":328,"status":133,"phases":329,"primaryCompletion":136,"completion":136,"start":297,"enrollment":261,"conditions":330,"interventions":331},"NCT02299401","Effectiveness of Two Regimens of Misoprostol Alone for Early Pregnancy Termination and Use of SQPT for At-Home Follow-Up",[49,50],[21],[45],{"trials":333,"activeCount":58},[334,343,351,355,359,363,367,371,380],{"nctId":335,"briefTitle":336,"status":133,"phases":337,"primaryCompletion":338,"completion":338,"start":136,"enrollment":339,"conditions":340,"interventions":341},"NCT02805426","Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage",[51],"2018-01",260,[15],[342,45],"Tranexamic Acid",{"nctId":344,"briefTitle":345,"status":66,"phases":346,"primaryCompletion":347,"completion":347,"start":136,"enrollment":348,"conditions":349,"interventions":350},"NCT02853552","Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding",[51],"2017-10",4330,[15],[45],{"nctId":155,"briefTitle":156,"status":133,"phases":352,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":353,"interventions":354},[51],[162],[74,45],{"nctId":186,"briefTitle":187,"status":143,"phases":356,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":357,"interventions":358},[51],[193,21],[74,45],{"nctId":196,"briefTitle":197,"status":133,"phases":360,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":361,"interventions":362},[51],[203],[74,45],{"nctId":206,"briefTitle":207,"status":143,"phases":364,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":365,"interventions":366},[51],[213],[74,45],{"nctId":216,"briefTitle":217,"status":133,"phases":368,"primaryCompletion":219,"completion":219,"start":220,"enrollment":181,"conditions":369,"interventions":370},[51],[18],[45,74],{"nctId":372,"briefTitle":373,"status":133,"phases":374,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":379},"NCT02226588","Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt",[51],"2016-01","2014-10",2827,[15],[45],{"nctId":224,"briefTitle":225,"status":143,"phases":381,"primaryCompletion":227,"completion":228,"start":229,"enrollment":211,"conditions":382,"interventions":383},[51],[231],[74,45],{"trials":385,"activeCount":86,"soonestReadout":44},[386,390,399,409,417,424,433,442,451,459,468,477,486,494,504,514,525,533],{"nctId":236,"briefTitle":237,"status":133,"phases":387,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":388,"interventions":389},[52],[243],[245,246],{"nctId":391,"briefTitle":392,"status":133,"phases":393,"primaryCompletion":297,"completion":297,"start":394,"enrollment":395,"conditions":396,"interventions":398},"NCT01485562","Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births",[52],"2012-05",84,[397],"Postpartum Haemorrhage",[45],{"nctId":400,"briefTitle":401,"status":133,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT00124540","Misoprostol for Preventing Postpartum Hemorrhage",[52],"2007-09","2007-10","2005-08",1200,[15],[246],{"nctId":410,"briefTitle":411,"status":133,"phases":412,"primaryCompletion":413,"completion":413,"start":394,"enrollment":414,"conditions":415,"interventions":416},"NCT01510574","A Study of Self-administered Misoprostol to Prevent Bleeding After Childbirth in the Community (MamaMiso)",[52],"2012-10",749,[15],[45],{"nctId":42,"briefTitle":43,"status":418,"phases":419,"primaryCompletion":44,"completion":420,"start":421,"enrollment":126,"conditions":422,"interventions":423},"RECRUITING",[],"2025-09","2024-07-24",[21],[45],{"nctId":425,"briefTitle":426,"status":133,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT01713153","Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal",[52],"2014-01","2012-06",1365,[15],[45],{"nctId":434,"briefTitle":435,"status":133,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT00466999","Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion",[52],"2009-11","2007-02",1000,[29],[246],{"nctId":443,"briefTitle":444,"status":133,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":450},"NCT00116480","Misoprostol in the Treatment of Postpartum Hemorrhage",[52],"2007-04","2005-12",61,[15],[45],{"nctId":452,"briefTitle":453,"status":133,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":181,"conditions":457,"interventions":458},"NCT01080846","Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage",[52],"2010-08","2010-02",[15],[45],{"nctId":460,"briefTitle":461,"status":133,"phases":462,"primaryCompletion":276,"completion":276,"start":463,"enrollment":464,"conditions":465,"interventions":466},"NCT00784186","Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial",[52],"2008-08",120,[26],[467,246],"mifepristone+misoprostol",{"nctId":469,"briefTitle":470,"status":133,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":476},"NCT01939457","400mcg Sublingual Misoprostol as First Line Treatment",[52],"2012-08","2011-09",641,[29],[45],{"nctId":478,"briefTitle":479,"status":133,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":485},"NCT02707653","Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research",[52],"2016-11","2016-03",75,[29],[45],{"nctId":487,"briefTitle":488,"status":133,"phases":489,"primaryCompletion":490,"completion":490,"start":240,"enrollment":491,"conditions":492,"interventions":493},"NCT00870272","Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)",[52],"2009-03",550,[26],[45],{"nctId":495,"briefTitle":496,"status":133,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":503},"NCT01508429","Misoprostol for Treatment of Postpartum Haemorrhage (PPH) in Home Births",[52],"2016-02","2012-07",70,[502],"Postpartum Hemorrhage (PPH)",[45],{"nctId":505,"briefTitle":506,"status":133,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT00120237","Misoprostol for the Prevention of Postpartum Hemorrhage in Rural Pakistan",[52],"2008-07","2005-07",1600,[15,512],"Anemia",[45],{"nctId":515,"briefTitle":516,"status":133,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":524},"NCT00670761","Misoprostol for the Treatment of Incomplete Abortion",[52],"2010-04","2010-12","2004-07",720,[523],"Abortion, Incomplete",[246],{"nctId":526,"briefTitle":527,"status":133,"phases":528,"primaryCompletion":529,"completion":529,"start":310,"enrollment":530,"conditions":531,"interventions":532},"NCT01462422","Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India",[52],"2014-03",3032,[15],[45,45],{"nctId":534,"briefTitle":535,"status":133,"phases":536,"primaryCompletion":537,"completion":537,"start":509,"enrollment":538,"conditions":539,"interventions":540},"NCT00116350","Misoprostol for the Treatment of Postpartum Hemorrhage",[52],"2008-01",1786,[15],[45,301],{"intervention":174,"totalTrials":8,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":561},{"trials":544,"activeCount":58},[],{"trials":546,"activeCount":58},[],{"trials":548,"activeCount":58},[],{"trials":550,"activeCount":58},[],{"trials":552,"activeCount":58},[553,557],{"nctId":165,"briefTitle":166,"status":66,"phases":554,"primaryCompletion":168,"completion":168,"start":158,"enrollment":169,"conditions":555,"interventions":556},[51],[171],[74,173,174],{"nctId":176,"briefTitle":177,"status":133,"phases":558,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":559,"interventions":560},[51],[183],[74,174],{"trials":562,"activeCount":58},[],{"intervention":564,"totalTrials":8,"cells":565},"Mifepristone and misoprostol",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":595},{"trials":567,"activeCount":58},[],{"trials":569,"activeCount":58},[],{"trials":571,"activeCount":58},[],{"trials":573,"activeCount":58},[],{"trials":575,"activeCount":58},[576,585],{"nctId":577,"briefTitle":578,"status":133,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT00997347","The Extended Gestational Age Medical Abortion Study",[51],"2012-02","2009-07",1400,[18],[564],{"nctId":586,"briefTitle":587,"status":133,"phases":588,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":594},"NCT01798017","Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh",[51],"2015-06","2015-08","2012-11",1738,[108],[564],{"trials":596,"activeCount":58},[],{"intervention":598,"totalTrials":8,"cells":599},"Mifepristone + Misoprostol",{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":626},{"trials":601,"activeCount":58},[],{"trials":603,"activeCount":58},[],{"trials":605,"activeCount":58},[],{"trials":607,"activeCount":58},[],{"trials":609,"activeCount":58},[610,618],{"nctId":611,"briefTitle":612,"status":133,"phases":613,"primaryCompletion":189,"completion":189,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT03346629","Outpatient Service for Mid-trimester Termination of Pregnancy",[51],"2017-12-01",230,[31],[598],{"nctId":619,"briefTitle":620,"status":133,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":464,"conditions":624,"interventions":625},"NCT05046041","Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal",[51],"2021-08-31","2020-11-25",[31],[598],{"trials":627,"activeCount":58},[],{"intervention":342,"totalTrials":86,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":644},{"trials":631,"activeCount":58},[],{"trials":633,"activeCount":58},[],{"trials":635,"activeCount":58},[],{"trials":637,"activeCount":58},[],{"trials":639,"activeCount":58},[640],{"nctId":335,"briefTitle":336,"status":133,"phases":641,"primaryCompletion":338,"completion":338,"start":136,"enrollment":339,"conditions":642,"interventions":643},[51],[15],[342,45],{"trials":645,"activeCount":58},[],{"intervention":647,"totalTrials":86,"cells":648},"Ibuprofen",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":669},{"trials":650,"activeCount":58},[],{"trials":652,"activeCount":58},[],{"trials":654,"activeCount":58},[],{"trials":656,"activeCount":58},[],{"trials":658,"activeCount":58},[659],{"nctId":660,"briefTitle":661,"status":133,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":668},"NCT01457521","Pain Control In First Trimester Medical Abortion: A Randomized Trial",[51],"2012-12","2011-10",250,[667],"Pain",[647],{"trials":670,"activeCount":58},[],{"intervention":672,"totalTrials":86,"cells":673},"IV Oxytocin + IM placebo",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":682,"NA":695},{"trials":675,"activeCount":58},[],{"trials":677,"activeCount":58},[],{"trials":679,"activeCount":58},[],{"trials":681,"activeCount":58},[],{"trials":683,"activeCount":58},[684],{"nctId":685,"briefTitle":686,"status":133,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":693},"NCT02954068","IV Versus IM Administration of Oxytocin for Postpartum Bleeding",[51],"2017-09-30","2017-10-01","2016-12-01",543,[15],[672,694],"IM Oxytocin + IV placebo",{"trials":696,"activeCount":58},[],{"intervention":694,"totalTrials":86,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":713},{"trials":700,"activeCount":58},[],{"trials":702,"activeCount":58},[],{"trials":704,"activeCount":58},[],{"trials":706,"activeCount":58},[],{"trials":708,"activeCount":58},[709],{"nctId":685,"briefTitle":686,"status":133,"phases":710,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":711,"interventions":712},[51],[15],[672,694],{"trials":714,"activeCount":58},[],{"intervention":173,"totalTrials":86,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":731},{"trials":718,"activeCount":58},[],{"trials":720,"activeCount":58},[],{"trials":722,"activeCount":58},[],{"trials":724,"activeCount":58},[],{"trials":726,"activeCount":58},[727],{"nctId":165,"briefTitle":166,"status":66,"phases":728,"primaryCompletion":168,"completion":168,"start":158,"enrollment":169,"conditions":729,"interventions":730},[51],[171],[74,173,174],{"trials":732,"activeCount":58},[],{"intervention":734,"totalTrials":86,"cells":735},"Mifepristone followed by misoprostol 24-48 hours later",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":754},{"trials":737,"activeCount":58},[],{"trials":739,"activeCount":58},[],{"trials":741,"activeCount":58},[],{"trials":743,"activeCount":58},[],{"trials":745,"activeCount":58},[746],{"nctId":747,"briefTitle":748,"status":133,"phases":749,"primaryCompletion":750,"completion":750,"start":297,"enrollment":751,"conditions":752,"interventions":753},"NCT02314754","Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation",[51],"2016-04",719,[18],[734],{"trials":755,"activeCount":58},[],{"intervention":757,"totalTrials":86,"cells":758},"Mifepristone + 2 doses of misoprostol 800 mcg",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":778},{"trials":760,"activeCount":58},[],{"trials":762,"activeCount":58},[],{"trials":764,"activeCount":58},[],{"trials":766,"activeCount":58},[],{"trials":768,"activeCount":58},[769],{"nctId":770,"briefTitle":771,"status":143,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":777},"NCT05119439","Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks",[51],"2023-06-30","2022-10-07",23,[18],[757],{"trials":779,"activeCount":58},[],{"intervention":781,"totalTrials":86,"cells":782},"Nifedipine",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":791,"NA":805},{"trials":784,"activeCount":58},[],{"trials":786,"activeCount":58},[],{"trials":788,"activeCount":58},[],{"trials":790,"activeCount":58},[],{"trials":792,"activeCount":58},[793],{"nctId":794,"briefTitle":795,"status":133,"phases":796,"primaryCompletion":797,"completion":798,"start":179,"enrollment":799,"conditions":800,"interventions":802},"NCT01912677","Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy",[51],"2017-09","2017-12",894,[801,23],"Hypertension in Pregnancy",[781,803,804],"Labetalol","Methyldopa",{"trials":806,"activeCount":58},[],{"intervention":803,"totalTrials":86,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":823},{"trials":810,"activeCount":58},[],{"trials":812,"activeCount":58},[],{"trials":814,"activeCount":58},[],{"trials":816,"activeCount":58},[],{"trials":818,"activeCount":58},[819],{"nctId":794,"briefTitle":795,"status":133,"phases":820,"primaryCompletion":797,"completion":798,"start":179,"enrollment":799,"conditions":821,"interventions":822},[51],[801,23],[781,803,804],{"trials":824,"activeCount":58},[],{"intervention":804,"totalTrials":86,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":841},{"trials":828,"activeCount":58},[],{"trials":830,"activeCount":58},[],{"trials":832,"activeCount":58},[],{"trials":834,"activeCount":58},[],{"trials":836,"activeCount":58},[837],{"nctId":794,"briefTitle":795,"status":133,"phases":838,"primaryCompletion":797,"completion":798,"start":179,"enrollment":799,"conditions":839,"interventions":840},[51],[801,23],[781,803,804],{"trials":842,"activeCount":58},[],{"intervention":844,"totalTrials":86,"cells":845},"Magnesium Sulfate",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":862},{"trials":847,"activeCount":58},[],{"trials":849,"activeCount":58},[],{"trials":851,"activeCount":58},[],{"trials":853,"activeCount":58},[],{"trials":855,"activeCount":58},[856],{"nctId":857,"briefTitle":858,"status":133,"phases":859,"primaryCompletion":498,"completion":498,"start":190,"enrollment":147,"conditions":860,"interventions":861},"NCT02091401","A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen",[51],[23],[844],{"trials":863,"activeCount":58},[],{"intervention":151,"totalTrials":86,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":878,"NA":880},{"trials":867,"activeCount":58},[],{"trials":869,"activeCount":58},[],{"trials":871,"activeCount":58},[],{"trials":873,"activeCount":58},[874],{"nctId":141,"briefTitle":142,"status":143,"phases":875,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":876,"interventions":877},[50],[149],[74,151],{"trials":879,"activeCount":58},[],{"trials":881,"activeCount":58},[],{"intervention":883,"totalTrials":86,"cells":884},"30 mg letrozole followed by 800 mcg misoprostol",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":886,"activeCount":58},[],{"trials":888,"activeCount":58},[],{"trials":890,"activeCount":58},[891],{"nctId":892,"briefTitle":893,"status":133,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":899},"NCT05207644","Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation",[49],"2022-04-30","2021-12-09",40,[21],[883],{"trials":901,"activeCount":58},[],{"trials":903,"activeCount":58},[],{"trials":905,"activeCount":58},[],{"intervention":907,"totalTrials":86,"cells":908},"estriol",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":910,"activeCount":58},[],{"trials":912,"activeCount":58},[913],{"nctId":914,"briefTitle":915,"status":133,"phases":916,"primaryCompletion":917,"completion":917,"start":918,"enrollment":919,"conditions":920,"interventions":922},"NCT00908570","Topical Estriol for Vaginal Health",[48],"2011-03","2009-06",104,[921],"Vaginal Health",[907],{"trials":924,"activeCount":58},[],{"trials":926,"activeCount":58},[],{"trials":928,"activeCount":58},[],{"trials":930,"activeCount":58},[],{"intervention":932,"totalTrials":933,"cells":934},"medical abortion",6,{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":954},{"trials":936,"activeCount":58},[],{"trials":938,"activeCount":58},[],{"trials":940,"activeCount":58},[],{"trials":942,"activeCount":58},[],{"trials":944,"activeCount":58},[945],{"nctId":946,"briefTitle":947,"status":133,"phases":948,"primaryCompletion":949,"completion":949,"start":252,"enrollment":950,"conditions":951,"interventions":953},"NCT01387256","Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone",[51],"2010-07",441,[952],"Complete Abortion",[932],{"trials":955,"activeCount":58},[956,965,973,982,990],{"nctId":957,"briefTitle":958,"status":133,"phases":959,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":963,"interventions":964},"NCT03931460","Feasibility of Medical Abortion by Telemedicine in Mexico",[],"2023-08-31","2019-04-01",1114,[21],[18],{"nctId":966,"briefTitle":967,"status":133,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":665,"conditions":971,"interventions":972},"NCT05028387","Telemedicine Medical Abortion Service Using the \"No-test\" Protocol in Ukraine and Uzbekistan.",[],"2022-12-31","2021-09-01",[21],[932],{"nctId":974,"briefTitle":975,"status":133,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT02513043","Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine",[],"2021-05-11","2016-03-22",1470,[21],[932],{"nctId":983,"briefTitle":984,"status":133,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":181,"conditions":988,"interventions":989},"NCT05459142","Telemedicine Medical Abortion Service Using the \"No-test\" Protocol in Azerbaijan.",[],"2022-11-30","2022-06-01",[84],[18],{"nctId":991,"briefTitle":992,"status":133,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":998},"NCT04599725","Feasibility of Telemedicine Medical Abortion",[],"2021-10-01","2020-10-01",413,[21],[932],{"intervention":1000,"totalTrials":32,"cells":1001},"Mifepristone, misoprostol",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":1003,"activeCount":58},[],{"trials":1005,"activeCount":58},[],{"trials":1007,"activeCount":58},[],{"trials":1009,"activeCount":58},[],{"trials":1011,"activeCount":58},[],{"trials":1013,"activeCount":58},[1014,1022,1030,1037],{"nctId":1015,"briefTitle":1016,"status":133,"phases":1017,"primaryCompletion":537,"completion":537,"start":405,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT00286208","Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation",[52],1443,[1020],"Induced Abortion",[1000],{"nctId":1023,"briefTitle":1024,"status":133,"phases":1025,"primaryCompletion":297,"completion":297,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1029},"NCT02018796","Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan",[],"2013-10",290,[952],[1000],{"nctId":1031,"briefTitle":1032,"status":133,"phases":1033,"primaryCompletion":310,"completion":310,"start":918,"enrollment":1034,"conditions":1035,"interventions":1036},"NCT01173003","Expansion Study of a Simplified Regimen of Medical Abortion Thru 63 Last Menstrual Period (LMP) in Tunisia",[52],688,[1020],[1000],{"nctId":1038,"briefTitle":1039,"status":133,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1045},"NCT00482209","Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation",[52],"2009-10","2007-05",1220,[1020],[1000,1046],"mifepristone, misoprostol",{"intervention":301,"totalTrials":32,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1061,"NA":1063},{"trials":1050,"activeCount":58},[],{"trials":1052,"activeCount":58},[],{"trials":1054,"activeCount":58},[],{"trials":1056,"activeCount":58},[1057],{"nctId":293,"briefTitle":294,"status":295,"phases":1058,"primaryCompletion":297,"completion":297,"start":298,"enrollment":58,"conditions":1059,"interventions":1060},[50],[15],[45,301],{"trials":1062,"activeCount":58},[],{"trials":1064,"activeCount":58},[1065,1073,1080],{"nctId":1066,"briefTitle":1067,"status":133,"phases":1068,"primaryCompletion":322,"completion":322,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1072},"NCT01914419","Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage",[52],"2014-04",4983,[15],[301],{"nctId":1074,"briefTitle":1075,"status":133,"phases":1076,"primaryCompletion":591,"completion":663,"start":394,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT01608958","IV vs IM Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage",[52],653,[15],[301,301],{"nctId":534,"briefTitle":535,"status":133,"phases":1081,"primaryCompletion":537,"completion":537,"start":509,"enrollment":538,"conditions":1082,"interventions":1083},[52],[15],[45,301],{"intervention":467,"totalTrials":11,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1103,"NA":1105},{"trials":1087,"activeCount":58},[],{"trials":1089,"activeCount":58},[],{"trials":1091,"activeCount":58},[],{"trials":1093,"activeCount":58},[1094],{"nctId":1095,"briefTitle":1096,"status":143,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":251,"enrollment":1099,"conditions":1100,"interventions":1101},"NCT00957346","Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)",[50],"2012-01",20,[26],[1102],"Mifepristone+misoprostol",{"trials":1104,"activeCount":58},[],{"trials":1106,"activeCount":58},[1107,1116],{"nctId":1108,"briefTitle":1109,"status":133,"phases":1110,"primaryCompletion":1111,"completion":1111,"start":918,"enrollment":1112,"conditions":1113,"interventions":1114},"NCT00969982","Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))",[52],"2013-06",238,[26],[467,1115],"misoprostol+placebo",{"nctId":460,"briefTitle":461,"status":133,"phases":1117,"primaryCompletion":276,"completion":276,"start":463,"enrollment":464,"conditions":1118,"interventions":1119},[52],[26],[467,246],{"intervention":1121,"totalTrials":8,"cells":1122},"Home administration of 200 mg mifepristone",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1124,"activeCount":58},[],{"trials":1126,"activeCount":58},[],{"trials":1128,"activeCount":58},[],{"trials":1130,"activeCount":58},[],{"trials":1132,"activeCount":58},[],{"trials":1134,"activeCount":58},[1135,1144],{"nctId":1136,"briefTitle":1137,"status":133,"phases":1138,"primaryCompletion":1139,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1143},"NCT02219100","Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus",[52],"2011-11","2010-11",613,[34],[1121],{"nctId":1145,"briefTitle":1146,"status":133,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT02398838","Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia",[52],"2012-04","2009-12",622,[34],[1121,1153],"Home or clinic administration of 400 mcg buccal misoprostol",{"intervention":1115,"totalTrials":86,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":58},[],{"trials":1159,"activeCount":58},[],{"trials":1161,"activeCount":58},[],{"trials":1163,"activeCount":58},[],{"trials":1165,"activeCount":58},[],{"trials":1167,"activeCount":58},[1168],{"nctId":1108,"briefTitle":1109,"status":133,"phases":1169,"primaryCompletion":1111,"completion":1111,"start":918,"enrollment":1112,"conditions":1170,"interventions":1171},[52],[26],[467,1115],{"intervention":1173,"totalTrials":86,"cells":1174},"800 mcg misoprostol via oral or buccal administration",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1176,"activeCount":58},[],{"trials":1178,"activeCount":58},[],{"trials":1180,"activeCount":58},[],{"trials":1182,"activeCount":58},[],{"trials":1184,"activeCount":58},[],{"trials":1186,"activeCount":58},[1187],{"nctId":1188,"briefTitle":1189,"status":133,"phases":1190,"completion":1191,"start":1192,"enrollment":406,"conditions":1193,"interventions":1194},"NCT00386867","A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP",[52],"2007-03","2006-10",[26],[1173],{"intervention":1196,"totalTrials":86,"cells":1197},"mifepristone-misoprostol treatment",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1199,"activeCount":58},[],{"trials":1201,"activeCount":58},[],{"trials":1203,"activeCount":58},[],{"trials":1205,"activeCount":58},[],{"trials":1207,"activeCount":58},[],{"trials":1209,"activeCount":58},[1210],{"nctId":1211,"briefTitle":1212,"status":133,"phases":1213,"primaryCompletion":917,"completion":917,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1217},"NCT00386282","Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol",[52],"2006-09",1250,[34],[1196],{"intervention":1219,"totalTrials":86,"cells":1220},"misprostol",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1222,"activeCount":58},[],{"trials":1224,"activeCount":58},[],{"trials":1226,"activeCount":58},[],{"trials":1228,"activeCount":58},[],{"trials":1230,"activeCount":58},[],{"trials":1232,"activeCount":58},[1233],{"nctId":1234,"briefTitle":1235,"status":295,"phases":1236,"enrollment":58,"conditions":1237,"interventions":1238},"NCT01487278","Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali",[52],[15],[1219],{"intervention":1153,"totalTrials":86,"cells":1240},{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1242,"activeCount":58},[],{"trials":1244,"activeCount":58},[],{"trials":1246,"activeCount":58},[],{"trials":1248,"activeCount":58},[],{"trials":1250,"activeCount":58},[],{"trials":1252,"activeCount":58},[1253],{"nctId":1145,"briefTitle":1146,"status":133,"phases":1254,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1255,"interventions":1256},[52],[34],[1121,1153],{"intervention":1258,"totalTrials":86,"cells":1259},"600 mcg misoprostol",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1261,"activeCount":58},[],{"trials":1263,"activeCount":58},[],{"trials":1265,"activeCount":58},[],{"trials":1267,"activeCount":58},[],{"trials":1269,"activeCount":58},[],{"trials":1271,"activeCount":58},[1272],{"nctId":1273,"briefTitle":1274,"status":133,"phases":1275,"completion":404,"start":1276,"enrollment":1277,"conditions":1278,"interventions":1279},"NCT00674232","Treatment of Incomplete Abortion With 600 Mcg Oral Misoprostol Compared to Standard Surgical Treatment",[52],"2006-05",311,[29],[1258]]